Nature Communications (Feb 2020)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

  • Maged Zeineldin,
  • Sara Federico,
  • Xiang Chen,
  • Yiping Fan,
  • Beisi Xu,
  • Elizabeth Stewart,
  • Xin Zhou,
  • Jongrye Jeon,
  • Lyra Griffiths,
  • Rosa Nguyen,
  • Jackie Norrie,
  • John Easton,
  • Heather Mulder,
  • Donald Yergeau,
  • Yanling Liu,
  • Jianrong Wu,
  • Collin Van Ryn,
  • Arlene Naranjo,
  • Michael D. Hogarty,
  • Marcin M. Kamiński,
  • Marc Valentine,
  • Shondra M. Pruett-Miller,
  • Alberto Pappo,
  • Jinghui Zhang,
  • Michael R. Clay,
  • Armita Bahrami,
  • Peter Vogel,
  • Seungjae Lee,
  • Anang Shelat,
  • Jay F. Sarthy,
  • Michael P. Meers,
  • Rani E. George,
  • Elaine R. Mardis,
  • Richard K. Wilson,
  • Steven Henikoff,
  • James R. Downing,
  • Michael A. Dyer

DOI
https://doi.org/10.1038/s41467-020-14682-6
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 20

Abstract

Read online

In most cancers, mutations that lead to oncogene activation and tumor suppressor inactivation synergize to promote tumorigenesis. However, in neuroblastomas, MYCN amplification and ATRX mutations are mutually exclusive and incompatible.